Tipranavir/Ritonavir Induction of Buprenorphine Glucuronide Metabolism in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone

REFERENCES

• Bruce RD. Medical interventions for addictions in the primary care setting. Top HIV Med 2010; 18(1):8–12.
   Google Scholar
• Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS: Aspects in treating HIV-infected drug users. AIDS 2010; 24(3):331–340.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 2006; 20(5):783–784.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5):563–572.
   PubMed Web of Science ®Google Scholar
• Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43(Suppl. 4):S216–S223.
   PubMed Web of Science ®Google Scholar
• Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy 2007; 18(4):262–270.
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 2006; 43(Suppl. 4):S224–S234.
   Google Scholar
• McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 2006; 43(Suppl. 4):S235–S246.
   Google Scholar
• Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21(1):149–179.
   PubMed Web of Science ®Google Scholar
• Vourvahis M, Dumond J, Patterson K, Rezk N, White N, Jennings S, Tien H, Sabo J, MacGregor T, Kashuba A. Effects of tipranavir/ritonavir on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein: Implications for drug interactions. In 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, 2007. Foundation for Retrovirology and Human Health.
   Google Scholar
• Kohle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 2009; 77:689–699.
   PubMed Web of Science ®Google Scholar
• Product Information: Aptivus (r), tipranavir. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., 2005.
   Google Scholar
• Baldwin JR, Borin MT, Ferry JJ, . Pharmacokinetic (PK) interaction between the HIV protease inhibitors tipranavir and ritonavir. In 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society of Microbiology, 1999.
   Google Scholar
• McCallister S, Sabo J, Galitz L, Mayers D. An open-label steady state investigation of the pharmacokinetics (PK) and tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) in normal healthy volunteers (BI 1182.5). 434-W. In 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA: Foundation for Retrovirology and Human Health. 2002.
   Google Scholar
• Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33(11):1729–1739.
   PubMed Web of Science ®Google Scholar
• Hanley WD, Wenning LA, Moreau A, Kost JT, Mangin E, Shamp T, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53(7):2752–2755.
   Google Scholar
• Beelen A, Balch A, Swabb E, Roalstad S, Kavitz K, Pleiman C, Smiley P, Sanguinetti E, Mather G. MPC-4326 drug-drug interaction profile. In 17th Conference on Retroviruses and Opportunistic Infections, 16–19 February 2010. San Francisco, CA, 2010. Foundation for Retrovirology and Human Health.
   Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12(5):577–581.
   PubMed Web of Science ®Google Scholar
• Iribarne C, Picart D, Dreano Y, Bail J-P BF. Involvement of cytochrome P450 3A4 in N-dealylation of buprenorphine in human liver micrsomes. Life Sci 1997; 60:1953–1964.
   PubMed Web of Science ®Google Scholar
• Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002; 306:31–39.
   PubMed Web of Science ®Google Scholar
• Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos 2005; 33:689–695.
   PubMed Web of Science ®Google Scholar
• King CD, Green MD, Rios GR, Coffman BL, Owens IS, Bishop WP, Tephly TR. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 1996; 332(1):92–100.
   PubMed Web of Science ®Google Scholar
• Green MD, King CD, Mojarrabi B, MacKenzie PI, Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998; 26(6):507–512.
   PubMed Web of Science ®Google Scholar
• Coffman BL, King CD, Rios GR, Tephly TR. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998; 26(1):73–77.
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 2009; 3:101–107.
   PubMedGoogle Scholar
• Rouguieg K, Picard N, Sauvage FL, Gaulier JM, Marquet P. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010; 38(1):40–45.
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, Liu-Chen L-Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001; 297(2):688–695.
   PubMed Web of Science ®Google Scholar
• Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272(2):505–510.
   PubMed Web of Science ®Google Scholar
• Kuhlman JJ, Jr., Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93(4):549–559.
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 2009; 105(3):234–239.
   Google Scholar
• Valdez H, Sabo J, Wruck J, MacGregor T, Garfinkel S, Chen L, Philip E, Mao Y, McCallister S, Norris S. Tipranavir (TPV) excretion mass balance and metabolite profile when co-administered with ritonavir (RTV). In 44th ICAAC. Washington, DC, 2004. Published by the American Society of Microbiology.
   Google Scholar
• Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther Drug Monit 2006; 28(2):245–251.
   Google Scholar
• Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 2010; 13(7):905–915.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87(6):735–742.
   PubMed Web of Science ®Google Scholar